EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cerebral spinal fluid analyses and therapeutic implications for leptomeningeal metastatic disease

Jie Wei Zhu, Megan Shum, Maleeha A Qazi, Arjun Sahgal, Sunit Das, Matthew Dankner, Ines Menjak, Mary Jane Lim-Fat, Katarzyna J Jerzak

Journal of Neuro-Oncology · 2025

DOI: 10.1007/s11060-024-04902-0 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neuro-Oncology, 2025. Verfasst von Jie Wei Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Meningeal Neoplasms, Biomarkers, Tumor, Meningeal Carcinomatosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 83 Literaturangaben. Gefördert von: Pfizer, Canadian Cancer Society Research Institute, Cancer Care Ontario.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To review applications of cerebral spinal fluid (CSF) biomarkers for the diagnosis, monitoring and treatment of leptomeningeal metastatic disease (LMD) among patients with metastatic solid tumors. METHODS: A narrative review identified original research related to CSF biomarkers among patients with metastatic solid tumors and LMD. Pre-clinical research (e.g. studies conducted in animal models) was not included. A descriptive analysis of literature was undertaken, with a focus on clinical applications related to the diagnosis, monitoring and treatment of LMD. RESULTS: The low cellularity of CSF in comparison to plasma is an advantage for liquid biopsy, given that circulating tumor DNA (ctDNA) is not significantly diluted by genomic DNA from non-cancer cells. This results in higher variant allelic frequencies and increased sensitivity in detecting ctDNA compared to plasma. However, the clinical significance of positive ctDNA and/or circulating tumor cells (CTCs) in the CSF, particularly in the absence of other signs of LMD (either clinical and/or radiological), remains unclear. While the use of CSF liquid biopsy to monitor treatment response is promising, this approach requires prospective validation using larger sample sizes prior to adoption in routine clinical care. Discovery efforts involving proteomics and metabolomics have potential to identify proteins involved in the regulation of energy metabolism, vasculature, and inflammation in LMD, which in turn, may offer insights into novel treatment approaches. CONCLUSION: CSF liquid biopsy should be incorporated in prospective studies for patients with LMD to validate promising diagnostic and/or predictive biomarkers of treatment response, as well as new therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Meningeal NeoplasmsBiomarkers, TumorMeningeal CarcinomatosisHumansCirculating Tumor DNAAnimalsNeoplastic Cells, CirculatingLiquid Biopsy

Stichwörter der Autor:innen

BiomarkersCerebral spinal fluidCirculating tumor cellsCirculating tumor DNALeptomeningeal metastatic diseaseLiquid biopsy

Substanzen

Biomarkers, TumorCirculating Tumor DNA

Autor:innen und Institutionen

  • Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
  • Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Department of Surgery, Division of Neurosurgery, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
  • Department of Medicine, McGill University, Montreal, QC, Canada.
  • Department of Medicine, Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.

Förderung

  • Pfizer
  • Canadian Cancer Society Research Institute
  • Cancer Care Ontario
  • Astra Zeneca
  • Eli Lilly

Zitieren

APA

Zhu, J. W., Shum, M., Qazi, M. A., Sahgal, A., Das, S., Dankner, M., Menjak, I., Lim-Fat, M. J., & Jerzak, K. J. (2025). Cerebral spinal fluid analyses and therapeutic implications for leptomeningeal metastatic disease. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04902-0

Vancouver

Zhu JW, Shum M, Qazi MA, Sahgal A, Das S, Dankner M, et al. Cerebral spinal fluid analyses and therapeutic implications for leptomeningeal metastatic disease. Journal of Neuro-Oncology. 2025. doi:10.1007/s11060-024-04902-0

BibTeX
@article{Zhu2025,
  author = {Zhu, Jie Wei and Shum, Megan and Qazi, Maleeha A and Sahgal, Arjun and Das, Sunit and Dankner, Matthew and Menjak, Ines and Lim-Fat, Mary Jane and Jerzak, Katarzyna J},
  title = {Cerebral spinal fluid analyses and therapeutic implications for leptomeningeal metastatic disease},
  journal = {Journal of Neuro-Oncology},
  year = {2025},
  doi = {10.1007/s11060-024-04902-0}
}
Kostenlos starten →